Children's Medical Center Corporation

Affinivax, Inc.

Genocea Biosciences, Inc.

University System of Maryland

Fundacao Butantan

Path Vaccine Solutions

Richard Malley

Yingjie Lu

Fan Zhang

Teresa J Broering

Velupillai Puvanesarajah

Shite Sebastian

George Rainer Siber

Todd Michael Gierahn

Kristin L Moffitt

Gilles R Besin

Taylor C Stevenson

Gang Yao

Onkar Sharma

Janet E McCombs

Francis Michon

Mark R Alderson

Jessica Baker Flechtner

Donna Ambrosino

Alan S Cross

Raphael Simon

Sharon Tennant

Jean-Francois Lucien Maisonneuve

Waldely De Oliveira Dias

Viviane Maimoni Gonçalves

Ying-jie Lu

Porter Anderson

Heidi Burke

George A Robertson

Andrea Maria Tate

Alan Cross

Jessica Flechtner

Technologies for the prevention and/or treatment of pneumococcal infections.

Multivalent pneumococcal vaccines

The present application is generally directed to methods for identifying immunogens from organisms and pathogens, and in particular for identifying immunogens which when administered as vaccines elicit a cellular and/or humoral immune response. The present application is also directed to pneumococcal T-cell immunogens, and vaccine compositions comprising one or a combination of pneumococcal immunogens and methods for treating or preventing pneumococcal infections using the vaccines thereof. The present invention also encompasses use of the pneumococcal immunogens for diagnostic purposes to identify a subject with a pneumococcal infection.

Immunogens and methods for discovery and screening thereof

Pneumococcal fusion protein vaccines

The present embodiments provide for a() Multiple Antigen Presenting System (MAPS) immunogenic composition comprising an immunogenic polysaccharide which induces an immune response, where at least onepeptide or polypeptide antigen is associated to the immunogenic polysaccharide by complementary affinity molecules. In some embodiments, the immunogenic polysaccharide can be an antigenic capsular polysaccharide of a, Type 5 (CP5) or Type 8 (CP8), or a combination of Type 5 or Type 8 capsular polysaccharide from, or alternatively, a different immunogenic capsular or noncapsular polysaccharide, and where the protein or peptideantigens are indirectly linked via an affinity binding pair. The present-MAPS immunogenic compositions can elicit both humoral and cellular immune responses to the immunogenic polysaccharide and one or multipleantigens at the same time.

Combined vaccine against mycobacterium tuberculosis

The present application is generally directed to novel pneumococcal polypeptide antigens and nucleic acids encoding such antigens, and immunogenic compositions comprising such antigens for treating and preventing pneumococcal infection. The present invention further provides method of using the antigens to elicits an immune response (e.g., IL-17A response, a T cell-mediated and/or B-cell-mediated immune responses). The present invention also provides methods of prophylaxis and/or treatment of pneumococcal-mediated diseases, such as sepsis, comprising administering an immunogenic composition including one or more of a combination of pneumococcal antigens or functional fragments thereof as disclosed herein. In some embodiments, one or more pneumococcal antigens can be present in a polysaccharide conjugate. The compositions induce an anti-pneumococcus immune response when administered to a mammal. The compositions can be used prophylactically to vaccinate an individual and/or therapeutically to induce a therapeutic immune response to an infected individual.

Protein antigens that provide protection against pneumococcal colonization and/or disease

The present embodiments provide for an immunogenic multiple antigen presenting system comprising a polymer to which antigens are associated by complementary affinity molecules. For example, the polymer can be a polysaccharide, or antigenic polysaccharide, to which protein or peptide antigens from the same or different pathogens are indirectly linked. The present immunogenic compositions can elicit both humoral and cellular immune responses to one or multiple antigens at the same time.

Multiple antigen presenting immunogenic composition, and methods and uses thereof

The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin fromand fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.

Modified biotin-binding protein, fusion proteins thereof and applications

Technologies for the prevention and/or treatment of nosocomial infections.

Immunogenic compositions

The present embodiments provide for an(SA) Multiple Antigen Presenting System (MAPS) immunogenic composition comprising an immunogenic polysaccharide which induces an immune response, where at least one(SA) peptide or polypeptide antigen is associated to the immunogenic polysaccharide by complementary affinity molecules. In some embodiments, the immunogenic polysaccharide can be an antigenic capsular polysaccharide of a Type 5 or Type 8 from, or alternatively, a different immunogenic capsular or noncapsular polysaccharide, and where the protein or peptide SA antigens are indirectly linked via an affinity binding pair. The present SA-MAPS immunogenic compositions can elicit both humoral and cellular immune responses to the immunogenic polysaccharide and one or multiple SA antigens at the same time.

Multiple antigen presenting system (MAPS)-basedvaccine, immunogenic composition, and uses thereof

Growing community of inventors

Beverly, MA, United States of America

Richard Malley